" class="no-js "lang="en-US"> AviadoBio Signs Agreement with Neurgain for Gene Therapy Tech
Sunday, April 14, 2024

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders and Neurgain Technologies, an innovative precision neurology company, today announced that the companies have entered into an exclusive license and collaboration agreement on an investigational novel subpial delivery technology for gene therapies targeting neurological diseases with spinal cord involvement.

“Subpial delivery has the potential to allow significantly lower doses of gene therapy to be delivered to patients, potentially reducing safety concerns whilst providing broad biodistribution,” said Professor Christopher Shaw, Co-Founder and Chief Scientific and Clinical Advisor, AviadoBio. “We look forward to leveraging subpial technology to advance gene therapies for people with neurological diseases such as ALS.”

Subpial delivery involves injection under the membrane that surrounds the spinal cord, and is intended to be a one-time, minimally invasive procedure. This technology has the potential to overcome the challenges of physical and biological barriers that limit biodistribution of therapeutic agents, while minimizing potential safety concerns associated with off-target exposure.

“We believe that subpial technology will help advance the next frontier of gene therapy delivery via the spinal cord. With AviadoBio’s expertise in neurodegenerative diseases, gene therapy development, and neurosurgical drug delivery, this agreement will allow us to potentially bring transformative treatments to people with neurological diseases like ALS,” said Professor Martin Marsala, Co-Founder and Chief Scientific Officer, Neurgain Technologies.

“We are taking a neuroanatomy-led approach to drug delivery, which should have utility beyond ALS, and across neurological diseases that involve the spinal cord. Whether through our own research and development efforts or through partnerships, we want to enable all possibilities to deliver effective treatments to patients,” said Lisa Deschamps, Chief Executive Officer, AviadoBio.

AviadoBio is currently employing subpial delivery as part of its pipeline of ALS gene therapies. Under the agreement, Neurgain has granted AviadoBio an exclusive worldwide license to develop, manufacture and commercialize subpial delivery technology.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more